Pharmacokinetics of single-dose rivaroxaban under fed state in obese vs. non-obese subjects: An open-label controlled clinical trial (RIVOBESE-PK).

However, the results demonstrated a decreasing trend (although not significant) of C max in the obese (339.7 ng/mL) and morbidly obese (317.3 ng/mL) compared with the non‐obese (392.9 ng/mL) populations.

also in 47,180 other papers

In addition, an increasing trend (although not significant) of MRT 0–inf in the obese (9.19 h) and morbidly obese (12.15 h) compared with the non‐obese (8.14 h) populations was observed.

also in 63,971 other papers